Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus
| العنوان: | Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus |
|---|---|
| المؤلفون: | Laurent Azoulay, Oriana Hoi Yun Yu, Dominique Hillaire-Buys, Hui Yin, Alan N. Barkun, Jean-Luc Faillie |
| المساهمون: | Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM), Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Jewish General Hospital, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), McGill University Health Center [Montreal] (MUHC), McGill University = Université McGill [Montréal, Canada], Herrada, Anthony |
| المصدر: | JAMA Internal Medicine JAMA Internal Medicine, American Medical Association, 2016, 176 (10), pp.1474-1481. ⟨10.1001/jamainternmed.2016.1531⟩ |
| بيانات النشر: | HAL CCSD, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, medicine.medical_treatment, Population, Gallbladder disease, 030209 endocrinology & metabolism, Bile Duct Diseases, Gallbladder Diseases, Type 2 diabetes, Gastroenterology, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Glucagon-Like Peptide 1, Internal medicine, Internal Medicine, medicine, Humans, Hypoglycemic Agents, Cholecystectomy, 030212 general & internal medicine, education, Proportional Hazards Models, Dipeptidyl-Peptidase IV Inhibitors, education.field_of_study, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, business.industry, Bile duct, Incidence, Gallbladder, medicine.disease, United Kingdom, 3. Good health, medicine.anatomical_structure, Diabetes Mellitus, Type 2, Cholecystitis, Female, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology |
| الوصف: | International audience; Importance:The use of dipeptidyl-peptidase-4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) analogues-a group of drugs used in the management of type 2 diabetes mellitus-may be associated with an increased risk of bile duct and gallbladder disease. To date, no observational study has assessed this possible association.Objective:To determine whether the use of DPP-4 inhibitors and GLP-1 analogues is associated with an increased risk of incident bile duct and gallbladder disease in patients with type 2 diabetes.Design, Setting, and Participants:A population-based cohort study linked the United Kingdom Clinical Practice Research Datalink with the Hospital Episodes Statistics database, yielding a cohort of 71 369 patients, 18 years or older, initiating an antidiabetic drug (including oral and injectable agents) between January 1, 2007, and March 31, 2014.Exposures:Current use of DPP-4 inhibitors and GLP-1 analogues (alone or in combination therapy) compared with current use of at least 2 oral antidiabetic drugs.Main Outcomes and Measures:Time-dependent Cox proportional hazards models were used to estimate hazard ratios (HRs) with 95% CIs of incident bile duct or gallbladder events (cholelithiasis, cholecystitis, cholangitis) causing hospitalization, comparing current use of DPP-4 inhibitors and GLP-1 analogues with current use of at least 2 oral antidiabetic drugs.Results:During 227 994 person-years of follow-up, 853 of the 71 369 patients were hospitalized for bile duct and gallbladder disease (incidence rate per 1000 person-years, 3.7; 95% CI, 3.5-4.0). Current use of DPP-4 inhibitors was not associated with an increased risk of bile duct and gallbladder disease compared with current use of at least 2 oral antidiabetic drugs (3.6 vs 3.3 per 1000 person-years; adjusted HR, 0.99; 95% CI, 0.75-1.32). In contrast, the use of GLP-1 analogues was associated with an increased risk of bile duct and gallbladder disease compared with current use of at least 2 oral antidiabetic drugs (6.1 vs 3.3 per 1000 person-years; adjusted HR, 1.79; 95% CI, 1.21-2.67). In a secondary analysis, GLP-1 analogues were also associated with an increased risk of cholecystectomy (adjusted HR, 2.08; 95% CI, 1.08-4.02).Conclusions and Relevance:The use of GLP-1 analogues was associated with an increased risk of bile duct and gallbladder disease. Physicians should be aware of this potential adverse event when prescribing these drugs. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2168-6106 2168-6114 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf849c160444282473daf6c75e8ae807Test https://hal.archives-ouvertes.fr/hal-01836887Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....cf849c160444282473daf6c75e8ae807 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 21686106 21686114 |
|---|